tigatuzumab monoclonal treatment cancer october clinical trial treatment pancreatic phase ii trials colorectal nonsmall cell lung ovarian completed drug targets member tumor necrosis factor receptor superfamily better known death receptor trail receptor protein limited expression normal tissues overexpressed many kinds tumours including colon gastric pancreatic lung phase study completed investigate biodistribution quantitative tumor uptake antitumor response patients metastatic colorectal cancer impacted objectives tracked use tracelabeling spect imaging course treatment found heterogeneity tigatuzumab uptake tumors tigatuzumab uptake dose dependent tigatuzumab uptake predictive clinical response treatment metastatic colorectal monoclonal article stub help wikipedia expanding antineoplastic immunomodulatory drug article stub help wikipedia expanding httpsenwikipediaorgwikitigatuzumab